Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Communication
  • Published:

Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration

European Journal of Clinical Nutrition volume 58, pages 110–115 (2004)Cite this article

Abstract

Objectives: Development of affordable and safe therapy to reverse the loss of body mass is of critical importance since AIDS-related wasting is associated with increased mortality.

Method: We have demonstrated earlier that oral therapeutic HIV vaccine, V-1 Immunitor (V1), tested in a small group of AIDS patients in Thailand not only increases T-cell counts and decreases the viral load but also results in weight gain and prolonged survival. To further expand this observation, we retrospectively analyzed 650 HIV-positive patients who were followed for an average of 23 weeks.

Results: The treatment with V1 resulted in a sustained and statistically significant increase in body mass across the whole population (mean±s.e.; 1.5±0.4 kg; P=6.5E−015). Among them, 384 (59%) patients gained an average of 4.2±0.2 kg; 107 (17%) had unchanged weight; and 159 (24%) had lost 3.8±0.3 kg. Thus, the prevailing majority of patients (76%) were able to gain or maintain weight. Treatment was well tolerated; in a survey of health status in a comparable but separate group of 382 patients, about 85% reported subjective improvement after V1 treatment, 6% reported no difference, and 9% of the patients reported minor adverse reactions, which did not last more than 1 week. Subjective improvement coincides with the reduction or clearance of oral thrush or mucocutaneous candidiasis in 87.5% of the patients.

Conclusions: In an open label setting, V1 increases body weight, subjective assessment of quality of life, and is safe and effective for HIV patients with weight loss. These data provide the impetus of using V-1 Immunitor as an affordable and easy-to-administer means of treating AIDS-associated wasting and opportunistic infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Baruchel S, Viau G, Olivier G, Bounous G & Wainberg MA (1996): Nutraceutical modulation of glutathione with a humanized native milk serum protein isolate Immunocal: application in AIDS and cancer. In: Oxidative Stress in Cancer AIDS and Neurodegenerative Diseases, eds L Montagnier, R Olivier & C Pasquier, pp 447–461. New York: Marcel Dekker.

    Google Scholar 

  • Batterham MJ & Garsia R (2001): A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int. J. Androl. 24, 232–240.

    Article  CAS  Google Scholar 

  • Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays RD & Beall G (2000): Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 283, 763–770.

    Article  CAS  Google Scholar 

  • Carbonnel F, Maslo C, Beaugerie L, Carrat F, Wirbel E, Aussel C, Gobert JG, Girard PM, Gendre JP, Cosnes J & Rozenbaum W (1998): Effect of indinavir on HIV-related wasting. AIDS 12, 1777–1784.

    Article  CAS  Google Scholar 

  • Clark RH, Feleke G, Din M, Yasmin T, Singh G, Khan FA & Rathmacher JA (2000): Nutritional treatment for acquired immunodeficiency virus-associated wasting using beta-hydroxy beta-methylbutyrate, glutamine, and arginine: a randomized, double-blind, placebo-controlled study. J. Parenter. Enter. Nutr. 24, 133–139.

    Article  CAS  Google Scholar 

  • de Luis Roman DA, Bachiller P, Izaola O, Romero E, Martin J, Arranz M, Eiros Bouza JM & Aller R (2001): Nutritional treatment for acquired immunodeficiency virus infection using an enterotropic peptide-based formula enriched with n-3 fatty acids: a randomized prospective trial. Eur. J. Clin. Nutr. 55, 1048–1052.

    Article  CAS  Google Scholar 

  • Farrar DJ (1999): Megestrol acetate: promises and pitfalls. AIDS Patient Care STDS 13, 149–152.

    Article  CAS  Google Scholar 

  • Gibert CL, Wheeler DA, Collins G, Madans M, Muurahainen N, Raghavan SS & Bartsch G (1999): Randomized, controlled trial of caloric supplements in HIV infection. Terry Beirn Community Programs for Clinical Research on AIDS. J. Acquir. Immune Defic. Syndr. 22, 253–259.

    Article  CAS  Google Scholar 

  • Gorter R, Seefried M & Volberding P (1992): Dronabinol effects on weight in patients with HIV infection. AIDS 6, 127–128.

    Article  CAS  Google Scholar 

  • Grinspoon S, Corcoran C, Askari H, Schoenfeld D, Wolf L, Burrows B, Walsh M, Hayden D, Parlman K, Anderson E, Basgoz N & Klibanski A (1998): Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 129, 18–26.

    Article  CAS  Google Scholar 

  • Hengge UR, Baumann M, Maleba R, Brockmeyer NH & Goos M (1996): Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection. Br. J. Nutr. 75, 129–138.

    Article  CAS  Google Scholar 

  • Izquierdo Villarroya B, Celaya Perez S & Amiguet Garcia JA (2000): Nutritional status of the HIV patient. Description and clinical course of a group of patients over a year. Nutr. Hosp. 15, 302–311.

    CAS  PubMed  Google Scholar 

  • Jirathitikal V & Bourinbaiar AS (2002): Safety and efficacy of an oral HIV vaccine (V-1 Immunitor) in AIDS patients at various stages of the disease. HIV Clin. Trials 3, 21–26.

    Article  Google Scholar 

  • Jirathitikal V, Metadilogkul O & Bourinbaiar AS (2002): Normalization of elevated liver enzymes due to V-1 Immunitor therapy. Antiviral Ther. 7(Suppl), L115–L116 (abstract).

    Google Scholar 

  • Jirathitikal V, Sooksathan P, Metadilogkul O & Bourinbaiar AS (2003): V-1 Immunitor: oral AIDS vaccine with therapeutic and prophylactic potential. Vaccine 21, 624–628.

    Article  CAS  Google Scholar 

  • Kaplan G, Thomas S, Fierer DS, Mulligan K, Haslett PA, Fessel WJ, Smith LG, Kook KA, Stirling D & Schambelan M (2000): Thalidomide for the treatment of AIDS-associated wasting. AIDS Res. Hum. Retrovirus 16, 1345–1355.

    Article  CAS  Google Scholar 

  • Keithley JK, Swanson B, Zeller JM, Sha BE, Cohen M, Hershow R & Novak R (2002): Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. J. Parenter. Enteral Nutr. 26, 6–14.

    Article  Google Scholar 

  • Metadilogkul O, Jirathitikal V & Bourinbaiar AS (2002): Survival of end-stage AIDS patients receiving V-1 Immunitor. HIV Clin. Trials 3, 258–259.

    Article  Google Scholar 

  • McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J & Gorbach S (2001): Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am. J. Clin. Nutr. 74, 679–686.

    Article  CAS  Google Scholar 

  • Mulligan K, Tai VW & Schambelan M (1999): Use of growth hormone and other anabolic agents in AIDS wasting. J. Parenter. Enteral Nutr. 23, S202–S209.

    Article  CAS  Google Scholar 

  • Rabkin JG, Wagner GJ & Rabkin R (1999): Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J. Clin. Psychopharmacol. 19, 19–27.

    Article  CAS  Google Scholar 

  • Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva JJ & Ruiz-Palacios GM (1996): Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS 10, 1501–1507.

    Article  CAS  Google Scholar 

  • Roubenoff R (2000): Acquired immunodeficiency syndrome wasting, functional performance, and quality of life. Am. J. Manag. Care 6, 1003–1016.

    CAS  PubMed  Google Scholar 

  • Scevola D, Di Matteo A, Uberti F, Minoia G, Poletti F & Faga A (2000): Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Read. 10, 365–375.

    CAS  PubMed  Google Scholar 

  • Schambelan M, Mulligan K, Grunfeld C, Daar ES, LaMarca A, Kotler DP, Wang J, Bozzette SA & Breitmeyer JB (1996): Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group. Ann. Intern. Med. 125, 873–882.

    Article  CAS  Google Scholar 

  • Shabert JK, Winslow C, Lacey JM & Wilmore DW (1999): Glutamine-antioxidant supplementation increases body cell mass in AIDS patients with weight loss: a randomized, double-blind controlled trial. Nutrition 15, 860–864.

    Article  CAS  Google Scholar 

  • Silva M, Skolnik PR, Gorbach SL, Spiegelman D, Wilson IB, Fernandez-DiFranco MG & Knox TA (1998): The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12, 1645–1651.

    Article  CAS  Google Scholar 

  • Singer P, Levine R, Rothkopf M & Askanazi J (1997): Home parenteral lipids in AIDS: a three-month study. Nutrition 13, 104–109.

    Article  CAS  Google Scholar 

  • Stack JA, Bell SJ, Burke PA & Forse RA (1996): High-energy, high-protein, oral, liquid, nutrition supplementation in patients with HIV infection: effect on weight status in relation to incidence of secondary infection. J. Am. Diet. Assoc. 96, 337–341.

    Article  CAS  Google Scholar 

  • Strawford A, Barbieri T, Neese R, Van Loan M, Christiansen M, Hoh R, Sathyan G, Skowronski R, King J & Hellerstein M (1999): Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 20, 137–146.

    Article  CAS  Google Scholar 

  • Struwe M, Kaempfer SH, Geiger CJ, Pavia AT, Plasse TF, Shepard KV, Ries K & Evans TG (1993): Effect of dronabinol on nutritional status in HIV infection. Ann. Pharmacother. 27, 827–831.

    Article  CAS  Google Scholar 

  • Taiwo BO (2000): HIV-associated wasting: brief review and discussion of the impact of oxandrolone. AIDS Patient Care STDS 14, 421–425.

    Article  CAS  Google Scholar 

  • Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G & Hinds CJ (1999): Increased mortality associated with growth hormone treatment in critically ill adults. N. Engl. J. Med. 341, 785–792.

    Article  CAS  Google Scholar 

  • Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J & Galetto G (1997): The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative. AIDS Res. Hum. Retrovir. 13, 305–315.

    Article  CAS  Google Scholar 

  • Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D & Gorbach SL (2000): Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 31, 803–805.

    Article  CAS  Google Scholar 

  • Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, Nightingale S, Gesundheit N, Watson D & Schade D (1996): Recombinant human growth hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125, 865–872.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank all individuals who participated in this study. We had warm support and encouragement from many patients and clinicians around the world and are thankful to all of them. All costs in developing V-1 Immunitor were borne by our families and friends.

Author information

Authors and Affiliations

  1. Immunitor Corporation Co., Ltd, Bangpakong Industrial Park, Chachoengsao, Thailand

    V Jirathitikal & A S Bourinbaiar

  2. Occupational and Environmental Medicine Association of Thailand, Rajavithi General Hospital, The Ministry of Public Health, Bangkok, Thailand

    O Metadilogkul

Authors
  1. V Jirathitikal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Metadilogkul
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A S Bourinbaiar
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Guarantor: Immunitor Corp., Co., Ltd.

Contributors: VJ, OM and ASB

Sponsorship: All support was provided by Immunitor Corporation.

Dr Metadilogkul was not paid by Immunitor for conduct of this study.

Corresponding author

Correspondence to A S Bourinbaiar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jirathitikal, V., Metadilogkul, O. & Bourinbaiar, A. Increased body weight and improved quality of life in AIDS patients following V-1 Immunitor administration. Eur J Clin Nutr 58, 110–115 (2004). https://doi.org/10.1038/sj.ejcn.1601756

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ejcn.1601756

Keywords

Search

Advanced search

Quick links